Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses a novel chemical compound inhibitor of…
Related Articles
MPN Workshop of the Carolinas 2024 | VJHemOnc
The MPN Workshop of the Carolinas is being held in Asheville, NC, from August 23 -25, 2024. This workshop brings together world-leading experts as they…
SOHO 2024 | VJHemOnc
The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO) will be held on September 4-7, 2024, in Houston, TX, and online. This meeting…
The importance of the MDT to provide adequate treatment and care to patients with amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, emphasizes the importance of using a multidisciplinary team (MDT) in the care of patients…
Insights into the treatment and management of BPDCN: CD123-targeted agents & combination therapy
VJHemOnc is pleased to share a feature article which explores treatment approaches for BPDCN. This article covers promising new therapies, drawing focus on the role of…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Practical advice for the management of patients with CML who are pregnant or wish to conceive
Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, summarizes her talk on fertility and pregnancy in patients with chronic myeloid leukemia (CML). Current…
The Chronic Lymphocytic Leukemia (CLL) Channel – VJHemOnc
Explore the latest Chronic Lymphocytic Leukemia (CLL) updates, including expert interviews, features, podcasts and e-learning on the VJHemOnc CLL Channel
The evolving use of selinexor in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the use of selinexor in the treatment of multiple myeloma,…
Treatment schedule for ruxolitinib in patients with MPNs and how to assess response
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, outlines the treatment schedule for ruxolitinib in patients with myeloproliferative neoplasms (MPNs) and discusses how to assess if…